Eilmeldung

INRoof Collapse at Under-Construction Temple Kills Seven, Injures 30 UKBrothers Divided: Siblings Set to Face Off at the World Cup INPrasidh Krishna's Five-Wicket Haul Seals Afghanistan's Fate in Chennai Heat INTLCMF Postpones New Phone Launch Due to High RAM Prices RUUbisoft Co-Founder Claude Guillemot Reportedly Dies in Plane Crash CRYPTO-ENPudgy Penguins NFT Project Expands to Target Stores Nationwide INTLBedford Train Crash Survivor Describes Horrific Scene INWhy India's Passport Ranks Lower Than Its Economic Might INBageerath, son of Union Minister Bandi Sanjay, granted interim bail AUAFL Saturday Scoreboard: Magpies lead Power, Blues win over Giants INRoof Collapse at Under-Construction Temple Kills Seven, Injures 30 UKBrothers Divided: Siblings Set to Face Off at the World Cup INPrasidh Krishna's Five-Wicket Haul Seals Afghanistan's Fate in Chennai Heat INTLCMF Postpones New Phone Launch Due to High RAM Prices RUUbisoft Co-Founder Claude Guillemot Reportedly Dies in Plane Crash CRYPTO-ENPudgy Penguins NFT Project Expands to Target Stores Nationwide INTLBedford Train Crash Survivor Describes Horrific Scene INWhy India's Passport Ranks Lower Than Its Economic Might INBageerath, son of Union Minister Bandi Sanjay, granted interim bail AUAFL Saturday Scoreboard: Magpies lead Power, Blues win over Giants

lp(a)

Stabil2 Meldungen2 QuellenZuletzt aktualisiert: 24.05.2026

Verwandte Themencholesterol cardiovascular disease lipoprotein(a)heart disease stroke genetics statins gene silencing

Neueste Meldungen

Genetic Blood Fat Lp(a) May Increase Heart Disease and Stroke Risk

24.05.2026KI-Zusammenfassung

Genetic Blood Fat Lp(a) May Increase Heart Disease and Stroke Risk

A genetic blood fat called Lp(a), found in about 1 in 5 people, may increase the risk of heart disease and stroke. It's not typically detected in standard cholesterol tests and is largely determined by genetics, making lifestyle changes less effective for lowering it.

Pharma Bets Big on Lp(a) Cholesterol Drugs With $5.6B Market Potential

Gesundheit·27.04.2026KI-Zusammenfassung

Pharma Bets Big on Lp(a) Cholesterol Drugs With $5.6B Market Potential

Novartis, Amgen and Eli Lilly are in late-stage trials for drugs targeting Lp(a), a dangerous form of cholesterol affecting one in five people worldwide. Novartis expects Phase 3 results mid-2026 for pelacarsen, with Amgen and Lilly following in 2027 and 2029. The drugs have shown 80%+ Lp(a) reduction but must now prove clinical benefit. If successful, the market could reach $5.6B by 2032, though less than 1% of U.S. adults currently get tested for Lp(a).